Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022

• Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma 

• Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, 

• AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with resectable, early-stage non-small cell lung cancer (NSCLC) accepted for a mini-oral presentation on pharmacodynamic and circulating tumor DNA dynamics in the study

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the ESMO (European Society for Medical Oncology) Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. 

A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2

• Abstract Number: 647TiP
• Session Type: Trial In Progress Poster
• Session Title: Haematological malignancies
• Session Date: Sunday Sept 11, 2022
• Presenter: Marianna Muller, MD, PharmD, Clinical Development Director at Innate Pharma

Oral presentation: Designing multispecific antibodies: ANKET for antigen-specific activation of NK cells

• Session Type: Special session
• Session Title: Next frontiers in drug discoveries
• Date and Time: Monday Sept 12, 2022 9:05 AM - 9:20 AM CEST
• Location: 7.3.U - Urval Auditorium
• Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma

Oral presentation: Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study [AstraZeneca-sponsored]

• Presentation #929MO
• Session Type: Mini Oral Session
• Session Title: Non-metastatic NSCLC and other thoracic malignancies
• Date and Time: Monday Sept 12, 2022 3:15 PM CEST
• Location: 7.3.O - Orléans Auditorium
• Presenter: Jonathan Spicer (Montreal, Canada)

The poster and presentations will be available on the Publications section of innate-pharma.com following the presentation.